UnityPhilly Response App for Overdose Reversal
Launched by DREXEL UNIVERSITY · Jun 14, 2024
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether an app called UnityPhilly can help save lives by encouraging people in the community to respond to opioid overdoses. The main goal is to see if more people will report overdoses and successfully use a medication called naloxone, which can reverse the effects of an opioid overdose, as they become more familiar with the app over time. Researchers will track how many overdose alerts are sent through the app compared to emergency medical service (EMS) calls, as well as how many successful overdose reversals happen by app users.
To be part of this study, you need to be at least 18 years old, have a smartphone with a data plan, and live or work in one of three specific neighborhoods in Philadelphia. If you participate, you will receive training on how to use the app and how to respond to overdoses, as well as follow-up surveys to share your experiences. This trial is not yet recruiting participants, but it aims to make a positive impact on opioid overdose responses in the community.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • owning a smartphone with a data package;
- • living or working in one of three identified Philadelphia neighborhoods;
- • aged 18 or older.
- Exclusion Criteria:
- • persons aged under 18 years of age
About Drexel University
Drexel University is a prominent research institution located in Philadelphia, Pennsylvania, known for its commitment to advancing knowledge through innovative research and education. As a clinical trial sponsor, Drexel University leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research aimed at improving health outcomes. The university fosters collaborations across various fields, including medicine, engineering, and public health, ensuring a comprehensive approach to addressing complex health challenges. With a focus on ethical standards and participant safety, Drexel University is dedicated to translating research findings into practical applications that enhance community well-being and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Stephen Lankenau, PhD
Principal Investigator
Drexel University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported